Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-152 · 1 trial · 1 indication
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| Arm | Type | Description |
|---|---|---|
| Part 1: Placebo | PLACEBO_COMPARATOR | - |
| Part 1 Cohort 1A: TC | EXPERIMENTAL | - |
| Part 1 Cohort 1B: TC | EXPERIMENTAL | - |
| Part 1 Cohort 1C: TC | EXPERIMENTAL | - |
| Part 2 Cohort 2A: TEZ/IVA | ACTIVE_COMPARATOR | - |
| Part 2 Cohort 2A: TC | EXPERIMENTAL | - |
| Part 2 Cohort 2B: TEZ/IVA | ACTIVE_COMPARATOR | - |
| Part 2 Cohort 2B: TC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VX-152 | DRUG | Tablet for oral administration. |
| TEZ/IVA | DRUG | Fixed-dose combination tablet for oral administration. |
| IVA | DRUG | Tablet for oral administration. |
| Placebo | DRUG | Placebo matched to VX-152. |
Inclusion Criteria: * Willing and able to comply with scheduled visits, treatment pan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures. * Body weight ≥35 kg. * Sweat chloride value ≥ 60 mmol/L from test results obtained during screening. * Subjects must ha...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
VX-152 is an investigational small molecule being developed for the treatment of cystic fibrosis. It is being studied in combination therapy for adults with the condition. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
VX-152 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy for cystic fibrosis.
VX-152 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. The drug is being studied in a completed Phase 2 trial that evaluated its safety in combination therapy for adults with cystic fibrosis.
VX-152 has been studied in one clinical trial, identified as NCT02951195. This was a Phase 2, randomized, double-blind, placebo-controlled study that evaluated the safety of VX-152 combination therapy in adults with cystic fibrosis. The trial enrolled 80 participants in the United States and has been completed.
VX-152 is a distinct investigational compound developed by Vertex Pharmaceuticals. It is being studied as a combination therapy for cystic fibrosis, but it is not the same as other approved Vertex medications. The drug is still in clinical development and has not been approved for use.